Last modified: 05 February 2010

Supporting Members

Patient organization-commercial company partnerships are sometimes viewed with scepticism by decision-makers and the general public. Some believe that pharmaceutical companies coerce patient organizations into conforming to their marketing agenda. In order to protect the Network's reputation and demonstrate that Myeloma Euronet does not conform to commercial agendas, the Network has adopted a detailed Funding Policy.

Supporting Members

2010

Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.

2009

Myeloma Euronet is supported by an unrestricted grant from Amgen Inc.
Myeloma Euronet is supported by an unrestricted grant from Celgene GmbH.
Myeloma Euronet is supported by an unrestricted grant from Celgene International Sàrl.
Myeloma Euronet is supported by an unrestricted grant from Janssen-Cilag GmbH.
Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech – A division of Janssen-Cilag AG.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
Myeloma Euronet is supported by an unrestricted grant from Roche.

2008

Myeloma Euronet is supported by an unrestricted grant from Celgene GmbH.
Myeloma Euronet is supported by an unrestricted grant from Celgene International Sàrl.
Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
Myeloma Euronet is supported by an unrestricted grant from Pharmion Ltd.
Myeloma Euronet is supported by an unrestricted grant from Roche.

2007

Myeloma Euronet is supported by an unrestricted grant from Amgen Inc.
Myeloma Euronet is supported by an unrestricted grant from Celgene GmbH.
Myeloma Euronet is supported by an unrestricted grant from Celgene International Sàrl.
Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
Myeloma Euronet is supported by an unrestricted grant from Pharmion Ltd.
Myeloma Euronet is supported by an unrestricted grant from Roche.
Myeloma Euronet is supported by an unrestricted grant from The Steel Charitable Trust.

2006

The Portuguese translation of this Web site was made possible through a restricted grant from Amgen Inc.
Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
Myeloma Euronet is supported by an unrestricted grant from Pharmion Ltd.
Myeloma Euronet is supported by an unrestricted grant from Roche.

2005

Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag, is the founding sponsor of Myeloma Euronet.
Myeloma Euronet is supported by an unrestricted grant from Ortho Biotech, Biopharmaceutical Division of Janssen-Cilag.
Myeloma Euronet is supported by an unrestricted grant from Novartis Pharma AG.

Latest News

Planned/active studies in multiple myeloma

Our new Web site section provides information on planned and active studies in the field of multiple myeloma. You can also announce studies that you ...

Survey results available now!

Myeloma Euronet is pleased to announce that the results of two recent international surveys on “Myeloma Treatment Side Effects and Unmet Patient ...

Myeloma Euronet’s new Annual Report is available now!

To find out more on our projects and activities, click here: More ...

Updated brochure on Bortezomib (Velcade^®)

An updated brochure on Bortezomib (Velcade®) for myeloma patients, their families and friends is now available for download from this Web site. The ...